This week on MedTech Global Insights, we explore a game-changing regulatory update from Brazil. ANVISA's new Resolution RDC 850/2024 allows medical device manufacturers to leverage their MDSAP certificate to extend the validity of their Brazil GMP certification, drastically simplifying market access.

This move is a powerful signal of the growing trend toward global regulatory harmonization. We discuss how MedTech companies can turn this trend into a significant competitive advantage, using a single audit process to unlock multiple international markets faster and more efficiently than ever before.

Case Study Highlight: A U.S.-based device manufacturer has full MDSAP certification. They've been hesitant to enter the complex Brazilian market due to the notoriously slow and expensive B-GMP audit process. How does this new resolution change their entire expansion timeline and budget overnight?

Key Takeaways This Episode:

- What exactly is Brazil's Resolution RDC 850/2024 and who does it apply to?

- How can leveraging an MDSAP certificate reduce audit fatigue and costs for your business?

- Is this part of a larger global trend, and which other countries are moving in this direction?

- What are the strategic implications for your company's global registration planning?

- How does this change the return on investment for pursuing MDSAP certification?

- Can this strategy be applied to other regions beyond Latin America?

Contact us at [email protected] or visit https://pureglobal.com/ or visit https://pureglobal.ai/ for FREE AI tools and a free medical device database.